<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02351115</url>
  </required_header>
  <id_info>
    <org_study_id>AMDC-002-202</org_study_id>
    <nct_id>NCT02351115</nct_id>
  </id_info>
  <brief_title>Staccato Alprazolam and Photoparoxysmal Response</brief_title>
  <official_title>Assessment of StaccatoÂ® Alprazolam on the EEG Photoparoxysmal Response in Patients With Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexza Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Epilepsy Study Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Alexza Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether people who usually have photosensitive&#xD;
      epilepsy will show a reduction in epileptic activity when they take a single dose of Staccato&#xD;
      Alprazolam as compared to placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine whether people who usually have photosensitive&#xD;
      epilepsy will show a reduction in epileptic activity when they take a single dose of Staccato&#xD;
      Alprazolam as compared to placebo. People with photosensitive epilepsy have changes on their&#xD;
      electroencephalogram (EEG) when shown flashing lights. Three dose levels of Staccato&#xD;
      Alprazolam will be compared to placebo.&#xD;
&#xD;
      This study will also assess the level of sedation of Staccato Alprazolam compared to placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Change From Pretreatment Baseline in the Standardized Photosensitivity Range (SPR)</measure>
    <time_frame>SPR was recorded pretreatment, 2, 10, 30 min, 1, 2, 4, and 6 hr post each study drug administration The maximum change from baseline occurred at: 10 min for alprazolam 2 mg, 1 hour for alprazolam 0.5 and 1 mg and placebo</time_frame>
    <description>Photosensitivity describes the presentation of an epileptiform EEG response (photoparoxysmal response) from exposure to intermittent photic stimulation (IPS). SPR is the number of frequency steps (2, 5, 8, 10, 13, 15, 18, 20, 23, 25, 30, 40, 50 and 60 Hz). between the upper and lower limits of sensitivity to IPS for that patient at that time, in order not to evoke seizures. Thus a reduction (-change) means the intervention is working (desired effect on sensitivity)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Sedation Using Visual Analog Scale (Sedated-Alert)</measure>
    <time_frame>Sedation was recorded pretreatment, 2, 10, 30 min, 1, 2, 4, and 6 hr post each study drug administration The maximum change from baseline occurred at:: 30 min for alprazolam 1 mg, 1 hour for alprazolam 0.5 and 2 mg, and 4 hours for placebo</time_frame>
    <description>Maximum change (in mm) from pretreatment baseline in level of sedation reported by the patient on a 100 mm line anchored by Sedated (0) and Alert (100)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Sedation Using Visual Analog Scale (Sleepy-Awake)</measure>
    <time_frame>Sleepiness was recorded pretreatment, 2, 10, 30 min, 1, 2, 4, and 6 hr post each study drug administration The maximum change from baseline occurred: at: 30 min for alprazolam 1 mg, 1 hour for alprazolam 0.5 and 2 mg and placebo</time_frame>
    <description>Maximum change (in mm) from pretreatment baseline in level of sedation reported by each subject on a 100 mm line anchored by Sleepy (0) and Awake (100)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of Plasma Concentrations of Alprazolam With Pharmacodynamic Effects on Standardized Photosensitivity Range (SPR)</measure>
    <time_frame>Pretreatment, 2, 10, 30 min, 1, 2, 4, and 6 hr post each study drug administration</time_frame>
    <description>Pearson correlation of all paired plasma concentrations of alprazolam (PK) with pharmacodynamic effect on SPR (PD) for each alprazolam dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of Plasma Concentrations of Alprazolam With Pharmacodynamic Effects on Visual Analog Scale (Sedated-Alert)</measure>
    <time_frame>Pretreatment, 2, 10, 30 min, 1, 2, 4, and 6 hr post each study drug administration</time_frame>
    <description>Pearson correlation of all paired plasma concentrations of alprazolam (PK) with pharmacodynamic effect on Sedation (PD) for each alprazolam dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of Plasma Concentrations of Alprazolam With Pharmacodynamic Effects on Visual Analog Scale (Sleepy-Awake)</measure>
    <time_frame>Pretreatment, 2, 10, 30 min, 1, 2, 4, and 6 hr post each study drug administration</time_frame>
    <description>Pearson correlation of all paired plasma concentrations of alprazolam (PK) with pharmacodynamic effect on Sleepiness (PD) for each alprazolam dose</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Sequence BEADC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 mg, D= Inhaled Alprazolam 2 mg, E=Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence CDAEB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 mg, D= Inhaled Alprazolam 2 mg, E=Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence DEBAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 mg, D= Inhaled Alprazolam 2 mg, E=Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence EDBAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 mg, D= Inhaled Alprazolam 2 mg, E=Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence CABED</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 mg, D= Inhaled Alprazolam 2 mg, E=Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A=Placebo</intervention_name>
    <arm_group_label>Sequence BEADC</arm_group_label>
    <arm_group_label>Sequence CABED</arm_group_label>
    <arm_group_label>Sequence CDAEB</arm_group_label>
    <arm_group_label>Sequence DEBAC</arm_group_label>
    <arm_group_label>Sequence EDBAC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B=Inhaled Alprazolam 0.5 mg</intervention_name>
    <arm_group_label>Sequence BEADC</arm_group_label>
    <arm_group_label>Sequence CABED</arm_group_label>
    <arm_group_label>Sequence CDAEB</arm_group_label>
    <arm_group_label>Sequence DEBAC</arm_group_label>
    <arm_group_label>Sequence EDBAC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C=Inhaled Alprazolam 1 m</intervention_name>
    <arm_group_label>Sequence BEADC</arm_group_label>
    <arm_group_label>Sequence CABED</arm_group_label>
    <arm_group_label>Sequence CDAEB</arm_group_label>
    <arm_group_label>Sequence DEBAC</arm_group_label>
    <arm_group_label>Sequence EDBAC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D= Inhaled Alprazolam 2 mg</intervention_name>
    <arm_group_label>Sequence BEADC</arm_group_label>
    <arm_group_label>Sequence CABED</arm_group_label>
    <arm_group_label>Sequence CDAEB</arm_group_label>
    <arm_group_label>Sequence DEBAC</arm_group_label>
    <arm_group_label>Sequence EDBAC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E=Placebo</intervention_name>
    <arm_group_label>Sequence BEADC</arm_group_label>
    <arm_group_label>Sequence CABED</arm_group_label>
    <arm_group_label>Sequence CDAEB</arm_group_label>
    <arm_group_label>Sequence DEBAC</arm_group_label>
    <arm_group_label>Sequence EDBAC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female subjects between the ages of 18 to 60 years, inclusive&#xD;
&#xD;
          -  Body mass index (BMI) â¥18 and â¤35 kg/m2&#xD;
&#xD;
          -  Able to speak, read, and understand English and willing and able to provide written&#xD;
             informed consent on an IRB-approved form before the initiation of any study procedures&#xD;
&#xD;
          -  A diagnosis and history of a photoparoxysmal response on EEG with or without a&#xD;
             diagnosis of epilepsy for which patients are on 0-2 concomitant antiepileptic drugs&#xD;
&#xD;
          -  At least 3 of the EEGs performed during the screen visit must have a reproducible&#xD;
             IPS-induced photoparoxysmal response (PPR) on EEG of at least 3 points on a frequency&#xD;
             assessment scale in at least one eye condition&#xD;
&#xD;
          -  In otherwise good general health as determined by a complete medical history, physical&#xD;
             examination, 12-lead ECG, blood chemistry profile, hematology, and urinalysis&#xD;
&#xD;
          -  Female participants (if of child-bearing potential and sexually active) and male&#xD;
             participants (if sexually active with a partner of child-bearing potential) who agree&#xD;
             to use a medically acceptable and effective birth control method throughout the study&#xD;
             and for 1 week following the end of the study. Medically acceptable methods of&#xD;
             contraception that may be used by the participant and/or his/her partner include&#xD;
             abstinence, birth control pills or patches, diaphragm with spermicide, intrauterine&#xD;
             device (IUD), surgical sterilization, and progestin implant or injection. Prohibited&#xD;
             methods include: the rhythm method, withdrawal, condoms alone, or diaphragm alone&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of non-epileptic seizures (e.g. metabolic, structural, or pseudo-seizures)&#xD;
&#xD;
          -  History of seizure worsening in response to narrow spectrum drugs&#xD;
&#xD;
          -  An active CNS infection, demyelinating disease, degenerative neurological disease or&#xD;
             any CNS disease deemed to be progressive during the course of the study that may&#xD;
             confound the interpretation of the study results&#xD;
&#xD;
          -  Use of more than 2 concomitant AEDs for epilepsy treatment&#xD;
&#xD;
          -  Subjects taking known inhibitors or inducers of CYP3A , including carbamazepine&#xD;
&#xD;
          -  Subjects with a history of allergic reactions to alprazolam or other benzodiazepines&#xD;
&#xD;
          -  Treatment with an investigational drug within 30 days (or within 5 half-lives of the&#xD;
             investigational drug, if &gt;30 days) before Visit 2&#xD;
&#xD;
          -  A history within the past 1 year of drug or alcohol dependence or abuse&#xD;
&#xD;
          -  Positive urine screen for drugs of abuse at Visit 1 - Screening&#xD;
&#xD;
          -  A history of HIV-positivity&#xD;
&#xD;
          -  Female subjects who have a positive pregnancy test at screening or prior to test&#xD;
             sessions or are breastfeeding&#xD;
&#xD;
          -  History of acute narrow angle glaucoma, Parkinson's disease, hydrocephalus, or history&#xD;
             of significant head trauma&#xD;
&#xD;
          -  Subjects who have a current history of asthma, chronic obstructive lung disease&#xD;
             (COPD), or any lung disease associated with bronchospasm&#xD;
&#xD;
          -  Subjects who use medications to treat airways disease, such as asthma or COPD&#xD;
&#xD;
          -  Subjects who have any acute respiratory signs/symptoms (e.g., wheezing)&#xD;
&#xD;
          -  Clinically significant ECG abnormality including (but not limited to) any of the&#xD;
             following conduction abnormalities or dysrhythmias: atrial fibrillation, mean QTcF (QT&#xD;
             interval corrected for heart rate using Fridericia's method) interval &gt;450 msec,&#xD;
             ventricular rate &lt;45 beats/min, second or third degree AV block, left bundle branch&#xD;
             block, or evidence of prior myocardial infarction (MI) or acute ischemia&#xD;
&#xD;
          -  Hypotension (systolic blood pressure â¤90 mm Hg, diastolic blood pressure â¤50 mm Hg),&#xD;
             or hypertension (systolic blood pressure â¥140 mm Hg, diastolic blood pressure â¥100 mm&#xD;
             Hg) measured while seated at screening or baseline&#xD;
&#xD;
          -  Significant hepatic, renal, gastroenterologic, cardiovascular (including ischemic&#xD;
             heart disease and congestive heart failure), endocrine, neurologic (including history&#xD;
             of seizures or stroke), or hematologic disease&#xD;
&#xD;
          -  Any other disease or condition, by history, physical examination, or laboratory&#xD;
             abnormalities that in the investigator's opinion, would present undue risk to the&#xD;
             subject, or may confound the interpretation of study results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J Isojarvi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Engage Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Consultants in Epilepsy &amp; Neurology, PLLC</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University Epilepsy Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania - Penn Epilepsy Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 19, 2015</study_first_submitted>
  <study_first_submitted_qc>January 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2015</study_first_posted>
  <results_first_submitted>August 1, 2019</results_first_submitted>
  <results_first_submitted_qc>July 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 10, 2021</results_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alprazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsInfo@alexza.com</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Within 10 days of request approval</ipd_time_frame>
    <ipd_access_criteria>Approval of formal request for access</ipd_access_criteria>
    <ipd_url>http://alexza.com</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BEADC</title>
          <description>Patient receiving treatment sequence BEADC</description>
        </group>
        <group group_id="P2">
          <title>CDAEB</title>
          <description>Patient receiving treatment sequence CDAEB</description>
        </group>
        <group group_id="P3">
          <title>DEBAC</title>
          <description>Patient receiving treatment sequence DEBAC</description>
        </group>
        <group group_id="P4">
          <title>EDBAC</title>
          <description>Patient receiving treatment sequence EDBAC</description>
        </group>
        <group group_id="P5">
          <title>CABED</title>
          <description>Patient receiving treatment sequence CABED</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All subjects treated</population>
      <group_list>
        <group group_id="B1">
          <title>BEADC BEADC</title>
          <description>Patient receiving treatment sequence BEADC</description>
        </group>
        <group group_id="B2">
          <title>CDAEB</title>
          <description>Patient receiving treatment sequence CDAEB</description>
        </group>
        <group group_id="B3">
          <title>DEBAC</title>
          <description>Patient receiving treatment sequence DEBAC</description>
        </group>
        <group group_id="B4">
          <title>EDBAC</title>
          <description>Patient receiving treatment sequence EDBAC</description>
        </group>
        <group group_id="B5">
          <title>CABED</title>
          <description>Patient receiving treatment sequence CABED</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="1"/>
            <count group_id="B4" value="1"/>
            <count group_id="B5" value="1"/>
            <count group_id="B6" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24" spread="0"/>
                    <measurement group_id="B2" value="23" spread="0"/>
                    <measurement group_id="B3" value="27" spread="0"/>
                    <measurement group_id="B4" value="39" spread="0"/>
                    <measurement group_id="B5" value="23" spread="0"/>
                    <measurement group_id="B6" value="27.2" spread="6.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Ethnicity</title>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Change From Pretreatment Baseline in the Standardized Photosensitivity Range (SPR)</title>
        <description>Photosensitivity describes the presentation of an epileptiform EEG response (photoparoxysmal response) from exposure to intermittent photic stimulation (IPS). SPR is the number of frequency steps (2, 5, 8, 10, 13, 15, 18, 20, 23, 25, 30, 40, 50 and 60 Hz). between the upper and lower limits of sensitivity to IPS for that patient at that time, in order not to evoke seizures. Thus a reduction (-change) means the intervention is working (desired effect on sensitivity)</description>
        <time_frame>SPR was recorded pretreatment, 2, 10, 30 min, 1, 2, 4, and 6 hr post each study drug administration The maximum change from baseline occurred at: 10 min for alprazolam 2 mg, 1 hour for alprazolam 0.5 and 1 mg and placebo</time_frame>
        <population>All 5 patients received all 4 treatments (crossover design)</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Placebo</title>
            <description>All patients receiving inhaled placebo in this 4 treatment complete crossover study</description>
          </group>
          <group group_id="O2">
            <title>Staccato Alprazolam, 0.5 mg</title>
            <description>All patients receiving 0.5 mg inhaled alprazolam in this 4 treatment complete crossover study</description>
          </group>
          <group group_id="O3">
            <title>Staccato Alprazolam, 1 mg</title>
            <description>All patients receiving 1 mg inhaled alprazolam in this 4 treatment complete crossover study</description>
          </group>
          <group group_id="O4">
            <title>Staccato Alprazolam, 2 mg</title>
            <description>All patients receiving 2 mg inhaled alprazolam in this 4 treatment complete crossover study</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Change From Pretreatment Baseline in the Standardized Photosensitivity Range (SPR)</title>
          <description>Photosensitivity describes the presentation of an epileptiform EEG response (photoparoxysmal response) from exposure to intermittent photic stimulation (IPS). SPR is the number of frequency steps (2, 5, 8, 10, 13, 15, 18, 20, 23, 25, 30, 40, 50 and 60 Hz). between the upper and lower limits of sensitivity to IPS for that patient at that time, in order not to evoke seizures. Thus a reduction (-change) means the intervention is working (desired effect on sensitivity)</description>
          <population>All 5 patients received all 4 treatments (crossover design)</population>
          <units>Number of frequency steps</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" lower_limit="-1.87" upper_limit="1.47"/>
                    <measurement group_id="O2" value="-4.4" lower_limit="-6.98" upper_limit="-1.82"/>
                    <measurement group_id="O3" value="-5.2" lower_limit="-7.85" upper_limit="-2.55"/>
                    <measurement group_id="O4" value="-4.8" lower_limit="-7.99" upper_limit="-1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Sedation Using Visual Analog Scale (Sedated-Alert)</title>
        <description>Maximum change (in mm) from pretreatment baseline in level of sedation reported by the patient on a 100 mm line anchored by Sedated (0) and Alert (100)</description>
        <time_frame>Sedation was recorded pretreatment, 2, 10, 30 min, 1, 2, 4, and 6 hr post each study drug administration The maximum change from baseline occurred at:: 30 min for alprazolam 1 mg, 1 hour for alprazolam 0.5 and 2 mg, and 4 hours for placebo</time_frame>
        <population>All 5 patients received each of the 4 treatments after washout (crossover design)</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Placebo</title>
            <description>All patients receiving inhaled placebo in this 4 treatment complete crossover study</description>
          </group>
          <group group_id="O2">
            <title>Staccato Alprazolam, 0.5 mg</title>
            <description>All patients receiving 0.5 mg inhaled alprazolam in this 4 treatment complete crossover study</description>
          </group>
          <group group_id="O3">
            <title>Staccato Alprazolam, 1 mg</title>
            <description>All patients receiving 1 mg inhaled alprazolam in this 4 treatment complete crossover study</description>
          </group>
          <group group_id="O4">
            <title>Staccato Alprazolam, 2 mg</title>
            <description>All patients receiving 2 mg inhaled alprazolam in this 4 treatment complete crossover study</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Sedation Using Visual Analog Scale (Sedated-Alert)</title>
          <description>Maximum change (in mm) from pretreatment baseline in level of sedation reported by the patient on a 100 mm line anchored by Sedated (0) and Alert (100)</description>
          <population>All 5 patients received each of the 4 treatments after washout (crossover design)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.3" lower_limit="-23.84" upper_limit="13.34"/>
                    <measurement group_id="O2" value="-58" lower_limit="-82.77" upper_limit="-33.23"/>
                    <measurement group_id="O3" value="-67.4" lower_limit="-87.47" upper_limit="-47.33"/>
                    <measurement group_id="O4" value="-70.6" lower_limit="-94.06" upper_limit="-47.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Sedation Using Visual Analog Scale (Sleepy-Awake)</title>
        <description>Maximum change (in mm) from pretreatment baseline in level of sedation reported by each subject on a 100 mm line anchored by Sleepy (0) and Awake (100)</description>
        <time_frame>Sleepiness was recorded pretreatment, 2, 10, 30 min, 1, 2, 4, and 6 hr post each study drug administration The maximum change from baseline occurred: at: 30 min for alprazolam 1 mg, 1 hour for alprazolam 0.5 and 2 mg and placebo</time_frame>
        <population>All 5 patients received each of the 4 treatments after washout (crossover design)</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Placebo</title>
            <description>All patients receiving inhaled placebo in this 4 treatment complete crossover study</description>
          </group>
          <group group_id="O2">
            <title>Staccato Alprazolam, 0.5 mg</title>
            <description>All patients receiving 0.5 mg inhaled alprazolam in this 4 treatment complete crossover study</description>
          </group>
          <group group_id="O3">
            <title>Staccato Alprazolam, 1 mg</title>
            <description>All patients receiving 1 mg inhaled alprazolam in this 4 treatment complete crossover study</description>
          </group>
          <group group_id="O4">
            <title>Staccato Alprazolam, 2 mg</title>
            <description>All patients receiving 2 mg inhaled alprazolam in this 4 treatment complete crossover study</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Sedation Using Visual Analog Scale (Sleepy-Awake)</title>
          <description>Maximum change (in mm) from pretreatment baseline in level of sedation reported by each subject on a 100 mm line anchored by Sleepy (0) and Awake (100)</description>
          <population>All 5 patients received each of the 4 treatments after washout (crossover design)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.2" lower_limit="-26.33" upper_limit="7.93"/>
                    <measurement group_id="O2" value="-54" lower_limit="-72.59" upper_limit="-35.31"/>
                    <measurement group_id="O3" value="-58.8" lower_limit="-76.01" upper_limit="-41.59"/>
                    <measurement group_id="O4" value="-58.8" lower_limit="-69.4" upper_limit="-48.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation of Plasma Concentrations of Alprazolam With Pharmacodynamic Effects on Standardized Photosensitivity Range (SPR)</title>
        <description>Pearson correlation of all paired plasma concentrations of alprazolam (PK) with pharmacodynamic effect on SPR (PD) for each alprazolam dose</description>
        <time_frame>Pretreatment, 2, 10, 30 min, 1, 2, 4, and 6 hr post each study drug administration</time_frame>
        <population>PK-PD population pairs, All 5 crossover subjects by alprazolam treatment received&#xD;
Number of PK-PD pairs per dose (n) = 35 (7 time points x 5 subjects)</population>
        <group_list>
          <group group_id="O1">
            <title>Staccato Alprazolam, 0.5 mg</title>
            <description>All patients receiving 0.5 mg inhaled alprazolam in this 4 treatment complete crossover study</description>
          </group>
          <group group_id="O2">
            <title>Staccato Alprazolam, 1 mg</title>
            <description>All patients receiving 1 mg inhaled alprazolam in this 4 treatment complete crossover study</description>
          </group>
          <group group_id="O3">
            <title>Staccato Alprazolam, 2 mg</title>
            <description>All patients receiving 2 mg inhaled alprazolam in this 4 treatment complete crossover study</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of Plasma Concentrations of Alprazolam With Pharmacodynamic Effects on Standardized Photosensitivity Range (SPR)</title>
          <description>Pearson correlation of all paired plasma concentrations of alprazolam (PK) with pharmacodynamic effect on SPR (PD) for each alprazolam dose</description>
          <population>PK-PD population pairs, All 5 crossover subjects by alprazolam treatment received&#xD;
Number of PK-PD pairs per dose (n) = 35 (7 time points x 5 subjects)</population>
          <units>correlation coefficient</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.454" spread="0.206"/>
                    <measurement group_id="O2" value="-0.534" spread="0.286"/>
                    <measurement group_id="O3" value="-0.410" spread="0.168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation of Plasma Concentrations of Alprazolam With Pharmacodynamic Effects on Visual Analog Scale (Sedated-Alert)</title>
        <description>Pearson correlation of all paired plasma concentrations of alprazolam (PK) with pharmacodynamic effect on Sedation (PD) for each alprazolam dose</description>
        <time_frame>Pretreatment, 2, 10, 30 min, 1, 2, 4, and 6 hr post each study drug administration</time_frame>
        <population>PK-PD population pairs, All 5 crossover subjects by alprazolam treatment received&#xD;
Number of PK-PD pairs per dose (n) = 35 (7 time points x 5 subjects)</population>
        <group_list>
          <group group_id="O1">
            <title>Staccato Alprazolam, 0.5 mg</title>
            <description>All patients receiving 0.5 mg inhaled alprazolam in this 4 treatment complete crossover study</description>
          </group>
          <group group_id="O2">
            <title>Staccato Alprazolam, 1 mg</title>
            <description>All patients receiving 1 mg inhaled alprazolam in this 4 treatment complete crossover study</description>
          </group>
          <group group_id="O3">
            <title>Staccato Alprazolam, 2 mg</title>
            <description>All patients receiving 2 mg inhaled alprazolam in this 4 treatment complete crossover study</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of Plasma Concentrations of Alprazolam With Pharmacodynamic Effects on Visual Analog Scale (Sedated-Alert)</title>
          <description>Pearson correlation of all paired plasma concentrations of alprazolam (PK) with pharmacodynamic effect on Sedation (PD) for each alprazolam dose</description>
          <population>PK-PD population pairs, All 5 crossover subjects by alprazolam treatment received&#xD;
Number of PK-PD pairs per dose (n) = 35 (7 time points x 5 subjects)</population>
          <units>correlation coefficient</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.350" spread="0.122"/>
                    <measurement group_id="O2" value="-0.567" spread="0.322"/>
                    <measurement group_id="O3" value="-0.623" spread="0.388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation of Plasma Concentrations of Alprazolam With Pharmacodynamic Effects on Visual Analog Scale (Sleepy-Awake)</title>
        <description>Pearson correlation of all paired plasma concentrations of alprazolam (PK) with pharmacodynamic effect on Sleepiness (PD) for each alprazolam dose</description>
        <time_frame>Pretreatment, 2, 10, 30 min, 1, 2, 4, and 6 hr post each study drug administration</time_frame>
        <population>PK-PD population pairs, All 5 crossover subjects by alprazolam treatment received&#xD;
Number of PK-PD pairs per dose (n) = 35 (7 time points x 5 subjects)</population>
        <group_list>
          <group group_id="O1">
            <title>Staccato Alprazolam, 0.5 mg</title>
            <description>All patients receiving 0.5 mg inhaled alprazolam in this 4 treatment complete crossover study</description>
          </group>
          <group group_id="O2">
            <title>Staccato Alprazolam, 1 mg</title>
            <description>All patients receiving 1 mg inhaled alprazolam in this 4 treatment complete crossover study</description>
          </group>
          <group group_id="O3">
            <title>Staccato Alprazolam, 2 mg</title>
            <description>All patients receiving 2 mg inhaled alprazolam in this 4 treatment complete crossover study</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of Plasma Concentrations of Alprazolam With Pharmacodynamic Effects on Visual Analog Scale (Sleepy-Awake)</title>
          <description>Pearson correlation of all paired plasma concentrations of alprazolam (PK) with pharmacodynamic effect on Sleepiness (PD) for each alprazolam dose</description>
          <population>PK-PD population pairs, All 5 crossover subjects by alprazolam treatment received&#xD;
Number of PK-PD pairs per dose (n) = 35 (7 time points x 5 subjects)</population>
          <units>correlation coefficient</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.449" spread="0.201"/>
                    <measurement group_id="O2" value="-0.582" spread="0.339"/>
                    <measurement group_id="O3" value="-0.586" spread="0.343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Each subject was questioned about adverse events (AEs) at 2 min, 10 min, 30 min, 1 hr, 2 hr, 4 hr, and 6 hr post study drug administration for each study drug.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Inhaled Placebo</title>
          <description>All patients receiving inhaled placebo in this 4 treatment complete crossover study</description>
        </group>
        <group group_id="E2">
          <title>StaccatoÂ® Alprazolam, 0.5 mg</title>
          <description>All patients receiving 0.5 mg inhaled alprazolam in this 4 treatment complete crossover study</description>
        </group>
        <group group_id="E3">
          <title>StaccatoÂ® Alprazolam, 1 mg</title>
          <description>All patients receiving 1 mg inhaled alprazolam in this 4 treatment complete crossover study</description>
        </group>
        <group group_id="E4">
          <title>StaccatoÂ® Alprazolam, 2 mg</title>
          <description>All patients receiving 2 mg inhaled alprazolam in this 4 treatment complete crossover study</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Oral dysaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Throat tightness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Engage Therapeutics, Inc</organization>
      <email>studydirector@engagetherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

